ATE352564T1 - Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle - Google Patents
Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelleInfo
- Publication number
- ATE352564T1 ATE352564T1 AT03706165T AT03706165T ATE352564T1 AT E352564 T1 ATE352564 T1 AT E352564T1 AT 03706165 T AT03706165 T AT 03706165T AT 03706165 T AT03706165 T AT 03706165T AT E352564 T1 ATE352564 T1 AT E352564T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- disease
- compounds
- treatments
- determination
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 7
- 238000010171 animal model Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 206010002022 amyloidosis Diseases 0.000 abstract 3
- 230000002490 cerebral effect Effects 0.000 abstract 3
- 208000024891 symptom Diseases 0.000 abstract 2
- 235000004252 protein component Nutrition 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36130202P | 2002-03-04 | 2002-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE352564T1 true ATE352564T1 (de) | 2007-02-15 |
Family
ID=27789108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03706165T ATE352564T1 (de) | 2002-03-04 | 2003-03-04 | Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040002460A1 (de) |
| EP (1) | EP1481007B1 (de) |
| JP (1) | JP2005535565A (de) |
| AT (1) | ATE352564T1 (de) |
| AU (1) | AU2003208212A1 (de) |
| CA (1) | CA2478636A1 (de) |
| DE (1) | DE60311433D1 (de) |
| NZ (1) | NZ535275A (de) |
| WO (1) | WO2003074558A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514407B2 (en) | 2002-03-04 | 2009-04-07 | Nymox Corporation | Spheron component peptides and pharmaceutical compositions |
| WO2004097420A1 (de) * | 2003-04-25 | 2004-11-11 | Biovision Ag | Verfahren zum nachweis einer neurologischen, demenziellen erkankung, die mit einer verschlechterung des kurz- oder langzeitgedächtnis einhergeht, zugehörige prosaas-peptide und nachweisreagenzien |
| PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| US8515882B2 (en) | 2010-11-18 | 2013-08-20 | International Business Machines Corporation | Efficient storage of individuals for optimization simulation |
| US8489526B2 (en) | 2010-11-24 | 2013-07-16 | International Business Machines Corporation | Controlling quarantining and biasing in cataclysms for optimization simulations |
| US9563844B2 (en) | 2011-06-30 | 2017-02-07 | International Business Machines Corporation | Speculative asynchronous sub-population evolutionary computing utilizing a termination speculation threshold |
| US9165247B2 (en) | 2012-01-04 | 2015-10-20 | International Business Machines Corporation | Using global and local catastrophes across sub-populations in parallel evolutionary computing |
| US9305257B2 (en) | 2013-05-20 | 2016-04-05 | International Business Machines Corporation | Adaptive cataclysms in genetic algorithms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
| US5525339A (en) * | 1986-08-27 | 1996-06-11 | Dms Pharmaceutical Inc. | Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2000508322A (ja) * | 1996-04-15 | 2000-07-04 | エヌワイエムオーエックス コーポレーション | バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法 |
| US6413940B1 (en) * | 1997-02-07 | 2002-07-02 | Nymox Corporation | Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS |
| US6130221A (en) * | 1997-03-05 | 2000-10-10 | Nymox Corporation | Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions |
| WO1999055839A1 (en) * | 1998-04-30 | 1999-11-04 | The Regents Of The University Of California | Host defense enhancement |
| GB9911802D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
-
2003
- 2003-03-04 CA CA002478636A patent/CA2478636A1/en not_active Abandoned
- 2003-03-04 JP JP2003573024A patent/JP2005535565A/ja active Pending
- 2003-03-04 DE DE60311433T patent/DE60311433D1/de not_active Expired - Lifetime
- 2003-03-04 WO PCT/CA2003/000295 patent/WO2003074558A2/en active IP Right Grant
- 2003-03-04 US US10/378,065 patent/US20040002460A1/en not_active Abandoned
- 2003-03-04 EP EP03706165A patent/EP1481007B1/de not_active Expired - Lifetime
- 2003-03-04 NZ NZ535275A patent/NZ535275A/en unknown
- 2003-03-04 AU AU2003208212A patent/AU2003208212A1/en not_active Abandoned
- 2003-03-04 AT AT03706165T patent/ATE352564T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005535565A (ja) | 2005-11-24 |
| NZ535275A (en) | 2007-03-30 |
| DE60311433D1 (de) | 2007-03-15 |
| CA2478636A1 (en) | 2003-09-12 |
| EP1481007A2 (de) | 2004-12-01 |
| EP1481007B1 (de) | 2007-01-24 |
| AU2003208212A1 (en) | 2003-09-16 |
| WO2003074558A2 (en) | 2003-09-12 |
| US20040002460A1 (en) | 2004-01-01 |
| WO2003074558A3 (en) | 2003-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200100803A2 (ru) | Способ имитации общественной реакции на стимулирующее воздействие | |
| ATE297755T1 (de) | Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind | |
| ATE300052T1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
| DK1348029T3 (da) | Materialer og fremgangsmåder involveret i proteinaggregering i neurodegenerative sygdomme | |
| ATE352564T1 (de) | Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle | |
| ATE404118T1 (de) | System für kontinuierliche leistungstests | |
| ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
| ATE427928T1 (de) | Fluorobenzamide zur behandlung von alzheimer oder seniler dementia | |
| DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
| ATE541923T1 (de) | Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit | |
| ATE304855T1 (de) | Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen | |
| ATE338142T1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| DE69619187T2 (de) | Verfahren zur behandlung von motorischen defiziten | |
| ATE316153T1 (de) | Diagnose des persönlichen risikos zur entwicklung von diabetischer retinopathie | |
| DE60318065D1 (de) | Fcyriia-transgenes tiermodell für autoimmunkrankheit | |
| WO2005061002A3 (en) | Composition and methods for modulating cns activity | |
| DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
| ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
| DE60334094D1 (de) | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden | |
| DE60321355D1 (de) | Verfahren zur reproduzierung von pleuromutilinen | |
| ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| DE60144164D1 (de) | Transgenes Tiermodel für neurodegenerative Krankheiten | |
| ATE554790T1 (de) | Verfahren und zusammensetzungen zur diagnose von asthma | |
| ATE396200T1 (de) | Reagenzien zur diagnose und behandlung von latexallergie und verfahren zu ihrer herstellung | |
| ATE397090T1 (de) | Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |